Predicting the Future of the Drug Industry: 2012 and Beyond
Now is a good time to look into our crystal balls and predict the future scenarios for the pharmaceutical industry. Let's take a slightly long-term view and predict how likely several scenarios will unfold in the next 5 to 8 years (ie, 2012 to 2019)
Pharmaceutical Cause Marketing
Pharmaceutical Cause Marketing
Pharma Use of Rx Data Survey
This surevy solicits your opinion on the benefits of pharma access to prescribing information, physicians ability to opt-out, and appropriate uses of Rx data by pharmaceutical companies.
Drug Risk Notification Survey
This survey asked respondents to evaluate the FDA's proposed Drug Watch program as well
as the proposal for a Drug Risk Advisory System.
What’s the Future of DTC Advertising?
Please take a few minutes to tell us your opinion of the future of Direct-to-Consumer (DTC) advertising of prescription medications under a new Democratic Administration. In this survey, please focus on the near future: ie, 2009 and 2010.
New Media Privacy Issues & Online Health Marketing
This survey asks YOUR opinion about the privacy issues raised in a brief filed with the FTC regarding the online marketing practices of pharmaceutical and other health-related companies.
Disease Mongering: Real or Fantasy?
Disease Mongering -- Is it real or not? Click here for survey results. Survey began 21 January 2007 Survey ended 11 February...
Buzz ‘n Blog Pharma Marketing Survey
This surevy solicits your opinion on specific marketing tactics involving CGC and buzz, specifically from a pharmaceutical marketing point of view.
Should Free Drug Samples Be Banned?
While the new PhRMA Code on Interactions with Healthcare Professionals bans free pens and lunches, it doesn't apply to samples. Should free drug samples also be banned? Take our survey and give us your opinion.
Potential for Bias in Commercially Supported CME
Please take 2 minutes to answer a few short questions relating to potential bias in continuing medical education (CME) programs supported by pharma/medical device companies and how to limit the need for industry funding of CME.
